Introduction Non–small-cell lung cancer (NSCLC) guidelines advise to screen stage III
NSCLC patients for brain metastases (BMs), preferably by magnetic resonance imaging …

INTRODUCTION: Stage III NSCLC patients are candidates for treatment with curative intent.
Current guidelines advise post contrast magnetic resonance imaging (MRI) or contrast …

Abstract Introduction Current National Comprehensive Cancer Network guidelines
recommend routine brain magnetic resonance imaging (MRI) screening in patients with …

Please see the Editorial Comment by Kazuhiro Tsuchiya discussing this article. To listen to
the podcast associated with this article, please select one of the following: iTunes, Google …

We aimed to discriminate subgroups according to the risk of brain metastases in patients
with non-small cell lung cancer (NSCLC) lacking neurological symptoms. We performed a …

Background: The exclusion of brain metastasis is important to determine the optimal
treatment plan in patients with non-small cell lung cancer (NSCLC). However, a routine …

The purpose of this prospective study was to determine whether using magnetic resonance
imaging (MRI) for early screening for brain metastases (BM) can improve quality of life …

Background To determine whether the distribution, staging features, or tumor histology of
non–small cell lung cancer (NSCLC) distinguishes neurologically symptomatic from …

PURPOSE: Those who have brain metastases smaller than 30mm in diameter and less than
5 in number can be treated less invasively with radiosurgery. This retrospective study …

Introduction Several clinical guidelines indicate that brain metastasis screening (BMS)
should be guided by disease stage in non‐small cell lung cancer (NSCLC). We estimate that …